Form 4: Puma Biotechnology CFO Maximo F. Nougues Sells Shares Under 10b5-1 Plan

Puma Biotechnology's CFO, Maximo F. Nougues, sold 4,156 shares of common stock at an average price of $3.7011 on July 17, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 17, 2024, Maximo F. Nougues, the Chief Financial Officer of Puma Biotechnology, sold 4,156 shares of the company's common stock.
• The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 14, 2020.
• The shares were sold at a weighted average price of $3.7011, with individual transaction prices ranging from $3.6001 to $3.8901.
• Following the transaction, Nougues directly owns 162,522 shares of Puma Biotechnology.
• The reporting person will provide full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote, upon request.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding an insider stock sale under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 plan are generally viewed as less impactful than discretionary sales, as they are pre-arranged.

Stakeholder Impact

• The sale of shares by a high-ranking officer may cause some investors to re-evaluate their positions, although the impact is likely to be minimal given the pre-arranged nature of the sale.

Key Dates